Mesoblast Limited (MEOBF)
Healthcare · PNK
Fundamentals
Valuation and ratings
Mesoblast Limited trades at USD1.70, which is 60% above the USD0.68 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 21 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
MEOBF earnings and analyst estimates
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
MEOBF passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Common questions
Is Mesoblast Limited (MEOBF) undervalued?
Against our discounted cash flow estimate of USD0.68, MEOBF at USD1.70 is 60% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
When does MEOBF report earnings next?
Mesoblast Limited is scheduled to report on 27 Aug 2026. Companies move earnings dates, so read it as scheduled rather than certain.
The full research page for MEOBF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.